NCT05554094View on ClinicalTrials.gov

Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
PTSDStress Disorders, TraumaticStress Disorders, Post-TraumaticTrauma and Stressor Related DisordersMental Disorder
Interventions
DRUG

Psilocybin

Participants will receive 15 mg of oral psilocybin in the first session and 25 mg in the second session.

Trial Locations (1)

43210

Ohio State University Department of Psychiatry and Behavioral Health at the Davis Medical Research Center, Columbus

All Listed Sponsors
lead

Ohio State University

OTHER